Unknown

Dataset Information

0

Evolved bacterial siderophore-mediated antibiotic cross-protection.


ABSTRACT: Antibiotic cross-protection enables resistant bacteria to protect other bacteria that would be otherwise susceptible to the drug. Cefiderocol is the first siderophore cephalosporin antibiotic approved for treating Gram-negative bacterial infections, including carbapenem-resistant Pseudomonas aeruginosa strains. While highly effective, CFDC resistance has been detected clinically, and mechanisms of resistance and cross-protection are not completely understood. In this study, we used experimental evolution and whole genome sequencing to identify cefiderocol resistance mechanisms and evaluated the trade-offs of evolving resistance. We found some cefiderocol-resistant populations evolved cross-protective social behavior, preventing cefiderocol killing of susceptible siblings. Notably, cross-protection was driven by increased secretion of bacterial iron-binding siderophores, which is unique from previously described antibiotic degradation mediated cross-protection. While concerning, we also showed that resistance can be selected against in drug-free environments. Deciphering the costs associated with antibiotic resistance might aid the development of evolution-informed therapeutic approaches to delay the evolution of antibiotic resistance.

SUBMITTER: Galdino ACM 

PROVIDER: S-EPMC10246284 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Evolved bacterial siderophore-mediated antibiotic cross-protection.

Galdino Anna Clara M ACM   Vaillancourt Mylene M   Celedonio Diana D   Huse Kara K   Doi Yohei Y   Lee Janet S JS   Jorth Peter P  

Research square 20230518


Antibiotic cross-protection enables resistant bacteria to protect other bacteria that would be otherwise susceptible to the drug. Cefiderocol is the first siderophore cephalosporin antibiotic approved for treating Gram-negative bacterial infections, including carbapenem-resistant <i>Pseudomonas aeruginosa</i> strains. While highly effective, CFDC resistance has been detected clinically, and mechanisms of resistance and cross-protection are not completely understood. In this study, we used experi  ...[more]

Similar Datasets

| S-EPMC4896713 | biostudies-literature
| S-EPMC6194032 | biostudies-literature
| S-EPMC7025823 | biostudies-literature
| S-EPMC11427687 | biostudies-literature
| S-EPMC5776446 | biostudies-literature
| S-EPMC6311597 | biostudies-other
| S-EPMC10786307 | biostudies-literature
| S-EPMC6943944 | biostudies-literature
| S-EPMC8245764 | biostudies-literature
| S-EPMC3599432 | biostudies-literature